Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or Risedronate

Overview

Patients who have received the appropriate number of years of alendronate or risedronate therapy will be recruited. Each patient will have received baseline BMD measurements performed at the spine and the hip by DXA. Each patient will receive tetracycline to label the bone and then have a transiliac bone biopsy. One year later teh bone label and biopsy procedure will be repeated.

Full Title of Study: “A Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Long-Term Alendronate or Risedronate”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2006

Arms, Groups and Cohorts

  • Alendronate 3 to < 5 years
    • Alendronate (any combination of 10 mg daily or 70 mg once weekly) 3- 5 years.
  • Risedronate 3 to < 5 Years
    • Risedronate (any combination of 5 mg daily or 35 mg once weekly) 3-5 years.
  • Alendronate ≥ 5 Years
    • Alendronate (any combination of 10 mg daily or 70 mg once weekly) for greater than or equal to 5 years.
  • Risedronate ≥ 5 Years
    • Risedronate (any combination of 5 mg daily or 35 mg once weekly) for greater than or equal to 5 years.

Clinical Trial Outcome Measures

Primary Measures

  • Differences in iliac crest bone histomorphometry and bone quality 9microarchitecture and matrix structure in PMO women receiving long term therapy with alendronate or risedronate
    • Time Frame: one year

Secondary Measures

  • Compare iliac crest bone histomorphometry and bone quality changes after 5 years of more of alendronate or risedronate therapy with 3 years of therapy in PMO women
    • Time Frame: one year

Participating in This Clinical Trial

Inclusion Criteria

  • Women at least 5 years postmenopausal – Subjects treated with any combination alendronate 10 mg daily or 70 mg once weekly or any combination of risedronate 5mg daily or 35 mg weekly for 3-5 years. Or subjects treated with any combination of alendronate 10 mg daily or 70 mg once weekly or any combination of risedronate 5mg daily or 35 mg weekly for greater than 5 years. Exclusion Criteria:

  • Presence of metabolic bone disease other than PMO – Use of any medication other than alendronate or risedronate within with in the past 6 months likely to interfere with skeletal homeostasis. Uncontrolled hyperthyroidism. Previous history of malignancy except treated squamous cell or basal cell carcinoma of the skin. – Alcohol or drug abuse, current or within the past 5 years. – Allergy to tetracycline, Novocain, or Versed. – Hip anatomy not conducive to transiliac bone biopsy or DXA scan. – Previous bilateral transiliac bone biopsies.

Gender Eligibility: Female

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Warner Chilcott
  • Collaborator
    • Sanofi
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Stephen R Marcello, MD, Study Director, Procter and Gamble

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.